Schedule 13G ownership disclosure

MOONLAKE IMMUNOTHERAPEUTICS

COMMON STOCK · CUSIP: 61559X104

Event date: 2024-12-31

Filing-level shares
3,343,643
Percent of class
5.3%
  • T. Rowe Price Associates, Inc.

    Shares: 3,343,643 · Class: 5.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000080255-25-000208
Form type
SCHEDULE 13G
Filer
MoonLake Immunotherapeutics
CIK
CIK 1821586
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub